Study Description
This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Enerzair inhalation capsule for up to 24 weeks under routine clinical practice.
The two different doses of Enerzair inhalation capsule via Breezhaler will be prescribed according to the approved label information in Korea, and the investigation for any additional diagnostic or monitoring will be not conducted for this study.
Interventions
Enerzair 150/50/160 μg
Enerzair 150/50/80 μg
Eligibility Criteria
Inclusion Criteria:
Adult patients (≥18 years of age) with a physician's diagnosis of asthma, who are prescribed Enerzair inhalation capsule (indacaterol acetate/ glycopyrronium bromide/mometasone furoate; 150/50/80, 150/50/160 μg) via Breezhaler, as per the approved label information
Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator
Exclusion Criteria:
Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required
Patients participating in other interventional clinical trials
Study Location
Novartis Investigative Site
Recruiting
Suncheon,Jeollanam-do,540-719,Korea, Republic of
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.